Therapeutic drug monitoring and pharmacokinetics of new coronavirus pneumonia antiviral drugs
10.12092/j.issn.1009-2501.2020.05.014
- VernacularTitle: 新型冠状病毒肺炎抗病毒药物的治疗药物监测及药代动力学研究进展
- Author:
Lu ZHANG
1
Author Information
1. Department of Pharmacy, Xiangya Hospital, Central South University, Xiangya Hospital, Central South University, Laboratory for Rational and Safe Use of Elderly
- Publication Type:Journal Article
- Keywords:
Adverse reactions;
Antiviral drugs;
New coronavirus pneumonia;
Pharmacokinetics;
Therapeutic drug monitoring
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2020;25(5):566-575
- CountryChina
- Language:Chinese
-
Abstract:
The recent outbreak of pneumonia caused by new coronavirus (SARS-CoV-2) infection has brought major challenges to public health and governance in various countries. At present, there is no clinically specific drug for SARS-CoV-2, and most of the antiviral drugs used are drugs for the treatment of severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS). This article aims to organize and analyze the antiviral drugs and their pharmacokinetic characteristics, and to discuss the characteristics and necessity of therapeutic drug monitoring (TDM), so as to provide a reference for the safety of anti-SARS-CoV-2 treatment.
